CD274 and gastric cancer: In the similar population-based study of nivolumab combined with paclitaxel plus ramucirumab as second-line treatment for advanced GC [15], the 6-month PFS rate was 46.5% (80% CI, 36.4%–55.8%), and median survival time was 13.1 months (95% CI, 8.0–16.6) as 60.5% of patients had PD-L1 CPS ≥ 1.